A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Rabusertib (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 11 Aug 2016 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 08 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.